Leaning Objectives
Upon completion of this activity, you should be able to:
- Evaluate the epidemiology, risk factors, comorbidities, and community aspects associated with HF to determine best practices for care.
- Incorporate GDMT, newer therapies, and interprofessional team strategies into treatment care plans for the management of HF to improve care coordination, communication, and patient outcomes.
Faculty
Alison Bailey, MD, FACC
Centennial Heart at Parkridge
Disclosure
Consultant Fees/Honoraria: BMS, Medtronic, OptumRx
Melvin Echols, MD, MSCR, FACC
Morehouse School of Medicine
Disclosure
Consultant Fees/Honoraria: Abbott Laboratories, Bayer Healthcare Pharmaceuticals, National Academy for Continuing Education, Novartis Corporation
Target Audience
The primary target audience for this education are members of the HF Care Team, including physicians, advanced practice providers (APPs), PharmDs, and other HCPs.
Important Dates
Date of Release: December 18, 2025
Term of Approval/Date of Expiration: December 15, 2026
Acknowledgement
This activity is supported by an unrestricted educational grant from Bayer AG.